These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24998960)

  • 1. Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.
    Kitagawa D; Horiguchi S; Yamashita T; Kuroi K; Shimizu K
    J Nippon Med Sch; 2014; 81(3):139-47. PubMed ID: 24998960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Difference in Prognostic Outcomes Between
    Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
    In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival differences among women with de novo stage IV and relapsed breast cancer.
    Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
    Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
    Wu X; Ye Y; Barcenas CH; Chow WH; Meng QH; Chavez-MacGregor M; Hildebrandt MA; Zhao H; Gu X; Deng Y; Wagar E; Esteva FJ; Tripathy D; Hortobagyi GN
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
    Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
    Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Malmgren JA; Mayer M; Atwood MK; Kaplan HG
    Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
    Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
    Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study.
    Chen W; Huang Y; Lewis GD; Szeja SS; Hatch SS; Farach A; Miltenburg D; Butler EB; Chang JC; Teh BS
    Clin Breast Cancer; 2018 Feb; 18(1):e97-e105. PubMed ID: 28888581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
    Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
    Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic factors associated with de novo metastatic breast cancer.
    Shen T; Siegal GP; Wei S
    Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.
    Shen T; Gao C; Zhang K; Siegal GP; Wei S
    Hum Pathol; 2017 Dec; 70():70-76. PubMed ID: 29031733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.